血红蛋白病的无创产前诊断:从概念到临床现实
本文为叙述性综述,探讨血红蛋白病的遗传基础与全球负担、现行筛查与侵入性诊断方法,并重点评估针对镰状细胞病和地中海贫血的无创产前诊断(NIPD)方法,包括相对单倍型剂量和相对突变剂量分析。多种NIPD策略显示有希望的结果,但胎儿分数变异、技术复杂性、成本和准确性仍是挑战,常规临床采用尚需进一步验证。
要点
- NIPD可实现更早诊断并消除操作相关流产风险,是侵入性产前诊断的潜在替代方案。
- 相对单倍型剂量和相对突变剂量是评估的主要NIPD方法学策略。
- 常规临床采用NIPD需进一步验证持续高诊断准确性、标准化方法并降低成本。
核心结论
- 多种NIPD策略在血红蛋白病产前诊断中显示有希望的结果,但常规临床采用仍需进一步验证以证明持续高诊断准确性,并需标准化方法和降低成本。
研究设计与样本
- 叙述性综述,评估已发表研究和临床试验中针对镰状细胞病和地中海贫血的NIPD证据。
主要发现
- NIPD可实现更早诊断并消除操作相关流产风险。
- NIPD面临胎儿分数变异、技术复杂性、成本和准确性等挑战。
- 全球在筛查和诊断服务可及性方面存在显著不平等,疾病负担较高地区尤为突出。
关键数值与推荐
- 主要方法学包括相对单倍型剂量和相对突变剂量。
- 现行确定性产前诊断依赖绒毛膜绒毛取样和羊膜腔穿刺,存在虽小但显著的妊娠丢失风险。
临床怎么用
- NIPD有潜力提高产前诊断的可接受性和利用率,但当前不应替代侵入性诊断用于常规临床。
局限性
- NIPD常规应用受限于胎儿分数变异、技术复杂性、成本和准确性。
- 全球筛查和诊断服务可及性存在显著不平等。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Haemoglobinopathies are the most prevalent monogenic disorders worldwide, contributing significantly to childhood morbidity and mortality. Preventive strategies, including carrier screening and prenatal diagnosis, have successfully reduced disease incidence in regions with established programmes. However, definitive prenatal diagnosis currently relies on invasive procedures, such as chorionic villus sampling and amniocentesis, which carry a small but significant risk of pregnancy loss. Non-invasive prenatal diagnosis (NIPD) offers a potential alternative that enables earlier diagnosis and eliminates procedure-related miscarriage risk. This narrative review explores the genetic basis and global burden of haemoglobinopathies, current screening strategies and the established invasive diagnostic approaches before critically evaluating the emergence of NIPD for sickle cell disease and thalassaemias. We summarise the principal methodological approaches, including relative haplotype dosage and relative mutation dosage, reviewing evidence from published studies and clinical trials. While multiple NIPD strategies demonstrate promising results, challenges remain including variable fetal fraction, technical complexity, cost and accuracy. Additionally, substantial global inequities persist regarding access to screening and diagnostic services, particularly in regions suffering from higher disease burden. Although NIPD could potentially improve the acceptability and uptake of prenatal diagnosis, routine clinical adoption for haemoglobinopathies requires further validation to demonstrate consistently high diagnostic accuracy, alongside standardised methodologies and reduced costs.
引用
- Leonidou I, Sallie L, Bell-Ricketts MJ, et al. Non-Invasive Prenatal Diagnosis of Haemoglobinopathies: From Concept to Clinical Reality. Prenat Diagn. 2026. PMID: 42879910. doi:10.1002/pd.70279
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。